(19)
(11) EP 3 735 462 A1

(12)

(43) Date of publication:
11.11.2020 Bulletin 2020/46

(21) Application number: 19705415.8

(22) Date of filing: 04.01.2019
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
C12N 15/864(2006.01)
 C12N 15/63(2006.01)
A61P 21/00(2006.01)
(86) International application number:
PCT/US2019/012300
(87) International publication number:
WO 2019/136216 (11.07.2019 Gazette 2019/28)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 05.01.2018 US 201862614121 P
07.03.2018 US 201862639871 P
16.05.2018 US 201862672255 P
29.08.2018 US 201862724341 P

(71) Applicant: The Board of Regents of The University of Texas System
Austin, TX 78701 (US)

(72) Inventors:
  • AMOASII, Leonela
    Dallas, TX 75390 (US)
  • OLSON, Eric, N.
    Dallas, TX 75390 (US)
  • MIN, Yi-li
    Dallas, TX 75390 (US)

(74) Representative: Potter Clarkson 
The Belgrave Centre Talbot Street
Nottingham NG1 5GG
Nottingham NG1 5GG (GB)

   


(54) THERAPEUTIC CRISPR/CAS9 COMPOSITIONS AND METHODS OF USE